Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 33Burkitt Lymphoma 32Lymphoma 30Leukemia, Myeloid, Acute 29Lymphoma, Non-Hodgkin 28Recurrence 26Breast Neoplasms 26Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 20Lymphoma, Follicular 20Leukemia, Lymphocytic, Chronic, B-Cell 20Hodgkin Disease 17Triple Negative Breast Neoplasms 16Leukemia 16Ovarian Neoplasms 15Hematologic Neoplasms 15Neuroblastoma 14Melanoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Lymphoma, Mantle-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 10Sarcoma 9Osteosarcoma 9Neoplasm Metastasis 9Lymphoma, B-Cell, Marginal Zone 9

Interventions

fludarabine 2Cyclophosphamide 2cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Injections 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Sclerosis × Cyclophosphamide × 90 days × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Gilead Sciences

Phase 1 Recruiting
52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡